TLP
CATX icon

Tri Locum Partners’s Perspective Therapeutics CATX Stock Holding History

Tri Locum Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-78,030
Closed -$929K – 30
2024
Q1 		$929K Buy
+78,030
New +$665K 0.32% 26

Other funds holding CATX

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Tri Locum Partners's CATX Position: Q2 2024 in Review

Tri Locum Partners sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 78,030 shares — an estimated $929K sold.

Tri Locum Partners first reported a position in CATX in Q1 2024 and held it in 1 quarter. The position peaked at $929K in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

  • Tri Locum Partners reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Tri Locum Partners sold 78,030 Perspective Therapeutics shares in Q2 2024, an estimated $929K.
  • Tri Locum Partners first reported a position in Perspective Therapeutics in Q1 2024 and held it in 1 quarter.
  • Tri Locum Partners's Perspective Therapeutics position peaked at $929K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Tri Locum Partners's 13F filing for Q2 2024, filed 14 Aug 2024.